
Opinion|Videos|February 28, 2025
The Value Proposition: Justifying the Investment in HS Centers of Excellence
Author(s)Jennifer Hsiao, MD
Panelist discusses how organizations can justify the cost of Centers of Excellence for HS by improving patient outcomes, reducing complications, and enhancing care efficiency. Metrics for evaluating multidisciplinary care include patient satisfaction, quality of life, clinical improvements, and reduction in hospitalizations.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How can organizations justify the effort/cost of establishing Centers of Excellence for HS?
- What metrics should be used to evaluate the effectiveness of multidisciplinary care in improving outcomes for HS patients?
Advertisement
Related to this article

In this Q&A, Konstantin Dmitrievich Penkov, MD, discusses delayed quality-of-life decline with cemiplimab plus chemotherapy in aNSCLC.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.
Advertisement
Advertisement
Trending on AJMC
1
Value-Based Pilot for Medicaid Members With Substance Use Disorder
2
Health Equity & Access Weekly Roundup: November 20, 2026
3
Four Ways to Boost Awareness, Access for COVID-19 PEP
4
Acne Treatment Adherence Ranges From 6% to 84% in Real-World Studies
5



